Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

3.66
1,585,684

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Top Ranked Momentum Stocks to Buy for June 7th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, June 7th:

    Top Ranked Momentum Stocks to Buy for June 5th

    Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, June 5th:

      Top Ranked Momentum Stocks to Buy for June 4th

      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 4th:

        Top Ranked Momentum Stocks to Buy for May 18th

        Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 18th:

          Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?

          Surging implied volatility makes AcelRx Pharmaceuticals (ACRX) lucrative to the option traders.

            Omeros Inks Agreement With FDA for OMS721 Phase III Trial

            Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

              Merck's Keytruda Gets Approved for Bladder Cancer in Japan

              Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.

                Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up

                FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.

                  5 Reasons to Pick Emergent as an Investment-Worthy Stock

                  Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.

                    Actinium Posts Positive DMC View on Lomab-B Phase III Trial

                    Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.

                      AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge

                      AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.

                        AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher

                        AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.

                          Arpita Dutt headshot

                          3 Biotech and Pharma Stocks with Key FDA Catalysts this October

                          Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.

                            Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options

                            Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

                              AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3%

                              AcelRx Pharmaceuticals, Inc.(ACRX) was a big mover last session, as the company saw its shares rise over 5% on the day.